Context of Vulnerability: A Powerful Paradigm for Targeted Oncology Drug Development
Renowned cancer researcher Dr. Daniel Von Hoff and his team at TGen are fervent believers in a new approach to developing novel therapies for... ... more>>
Tags: cancer,
oncology,
biotech,
pharma,
biotechnology,
clinical trials,
phase I,
drug development,
clinical research,
CRO,
Medelis,
Dan Von Hoff,
TGen,
pancreatic cancer
97 views
language: English
The Lost Art of Phase I Oncology Clinical Trials
Traditionally, oncology drug developers have regarded the phase I clinical trial as having a utility limited to the assessment of safety,... ... more>>
Tags: oncology,
cancer,
clinical trial,
biotech,
biotechnology,
pharma,
drug development,
cro,
contract research,
phase I,
phase 1
40 views
language: English
Medelis: An Introduction to our Oncology CRO Services in the U.S., Europe and Asia
General introductory presentation to Medelis' oncology CRO services in the U.S., Europe and Asia. more>>
Tags: medelis,
oncology,
CRO,
contract research,
clinical trial,
phase 1,
phase 2,
phase I,
phase II,
clinical research,
CRO
118 views
language: English
Patient Safety in Clinical Trials: An Interview with James Gourzis, M.D., Ph.D.
Patient safety has always been the industry’s focus during clinical trials. However, a recent spate of well-publicized patient safety issues have... ... more>>
Tags: patient safety,
clinical trials,
oncology,
biotech,
biotechnology,
pharma,
pharmaceutical,
CRO,
Medelis,
James Gourzis,
clinical research,
contract research
74 views
language: English
Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster
A Q&A with Dr. Mike McGarry, VP of Preclinical Study at Medelis. He describes a nuanced preclinical study process that can help a biotech Chief... ... more>>
Tags: biotech,
biotechnology,
pharma,
pharmaceutical,
preclinical research,
preclinical study,
clinical research,
contract research,
CRO,
Medelis,
oncology,
Mike McGarry
144 views
language: English
65 views
language: English